
Global Radiopharmaceuticals in Nuclear Medicine Market by Size, by Type, by Application, by Region, History and Forecast 2020-2031
Description
Summary
According to APO Research, The global Radiopharmaceuticals in Nuclear Medicine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Radiopharmaceuticals in Nuclear Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Radiopharmaceuticals in Nuclear Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Radiopharmaceuticals in Nuclear Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Radiopharmaceuticals in Nuclear Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Radiopharmaceuticals in Nuclear Medicine include Aurobindo Pharma, Bracco Imaging, Cardinal Health, Curium Pharma, GE Healthcare, Jubilant Pharma, Lantheus, Mundipharma and Novartis, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Radiopharmaceuticals in Nuclear Medicine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Radiopharmaceuticals in Nuclear Medicine, also provides the sales of main regions and countries. Of the upcoming market potential for Radiopharmaceuticals in Nuclear Medicine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Radiopharmaceuticals in Nuclear Medicine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Radiopharmaceuticals in Nuclear Medicine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Radiopharmaceuticals in Nuclear Medicine sales, projected growth trends, production technology, application and end-user industry.
Radiopharmaceuticals in Nuclear Medicine Segment by Company
Aurobindo Pharma
Bracco Imaging
Cardinal Health
Curium Pharma
GE Healthcare
Jubilant Pharma
Lantheus
Mundipharma
Novartis
SIEMENS
Bayer
Dongcheng
Eli Lilly
China Isotope & Radiation
Radiopharmaceuticals in Nuclear Medicine Segment by Type
Diagnostic Radiopharmaceuticals
Therapy Radiopharmaceuticals
Radiopharmaceuticals in Nuclear Medicine Segment by Application
Oncology
Cardiology
Other
Radiopharmaceuticals in Nuclear Medicine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiopharmaceuticals in Nuclear Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Radiopharmaceuticals in Nuclear Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiopharmaceuticals in Nuclear Medicine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Radiopharmaceuticals in Nuclear Medicine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Radiopharmaceuticals in Nuclear Medicine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Radiopharmaceuticals in Nuclear Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Radiopharmaceuticals in Nuclear Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
According to APO Research, The global Radiopharmaceuticals in Nuclear Medicine market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Radiopharmaceuticals in Nuclear Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Radiopharmaceuticals in Nuclear Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The China market for Radiopharmaceuticals in Nuclear Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Radiopharmaceuticals in Nuclear Medicine is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global manufacturers of Radiopharmaceuticals in Nuclear Medicine include Aurobindo Pharma, Bracco Imaging, Cardinal Health, Curium Pharma, GE Healthcare, Jubilant Pharma, Lantheus, Mundipharma and Novartis, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
This report presents an overview of global market for Radiopharmaceuticals in Nuclear Medicine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020-2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Radiopharmaceuticals in Nuclear Medicine, also provides the sales of main regions and countries. Of the upcoming market potential for Radiopharmaceuticals in Nuclear Medicine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Radiopharmaceuticals in Nuclear Medicine sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Radiopharmaceuticals in Nuclear Medicine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Radiopharmaceuticals in Nuclear Medicine sales, projected growth trends, production technology, application and end-user industry.
Radiopharmaceuticals in Nuclear Medicine Segment by Company
Aurobindo Pharma
Bracco Imaging
Cardinal Health
Curium Pharma
GE Healthcare
Jubilant Pharma
Lantheus
Mundipharma
Novartis
SIEMENS
Bayer
Dongcheng
Eli Lilly
China Isotope & Radiation
Radiopharmaceuticals in Nuclear Medicine Segment by Type
Diagnostic Radiopharmaceuticals
Therapy Radiopharmaceuticals
Radiopharmaceuticals in Nuclear Medicine Segment by Application
Oncology
Cardiology
Other
Radiopharmaceuticals in Nuclear Medicine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiopharmaceuticals in Nuclear Medicine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Radiopharmaceuticals in Nuclear Medicine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiopharmaceuticals in Nuclear Medicine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Provides an overview of the Radiopharmaceuticals in Nuclear Medicine market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2020-2031).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Radiopharmaceuticals in Nuclear Medicine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Radiopharmaceuticals in Nuclear Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Radiopharmaceuticals in Nuclear Medicine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
195 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Radiopharmaceuticals in Nuclear Medicine Market Size, 2020 VS 2024 VS 2031
- 1.3 Global Radiopharmaceuticals in Nuclear Medicine Market Size Estimates and Forecasts (2020-2031)
- 1.4 Global Radiopharmaceuticals in Nuclear Medicine Sales Estimates and Forecasts (2020-2031)
- 1.5 Global Radiopharmaceuticals in Nuclear Medicine Market Average Price (2020-2031)
- 1.6 Assumptions and Limitations
- 1.7 Study Goals and Objectives
- 2 Global Radiopharmaceuticals in Nuclear Medicine Market Dynamics
- 2.1 Radiopharmaceuticals in Nuclear Medicine Industry Trends
- 2.2 Radiopharmaceuticals in Nuclear Medicine Industry Drivers
- 2.3 Radiopharmaceuticals in Nuclear Medicine Industry Opportunities and Challenges
- 2.4 Radiopharmaceuticals in Nuclear Medicine Industry Restraints
- 3 Radiopharmaceuticals in Nuclear Medicine Market by Manufacturers
- 3.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Manufacturers (2020-2025)
- 3.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Manufacturers (2020-2025)
- 3.3 Global Radiopharmaceuticals in Nuclear Medicine Average Sales Price by Manufacturers (2020-2025)
- 3.4 Global Radiopharmaceuticals in Nuclear Medicine Industry Manufacturers Ranking, 2023 VS 2024 VS 2025
- 3.5 Global Radiopharmaceuticals in Nuclear Medicine Key Manufacturers Manufacturing Sites & Headquarters
- 3.6 Global Radiopharmaceuticals in Nuclear Medicine Manufacturers, Product Type & Application
- 3.7 Global Radiopharmaceuticals in Nuclear Medicine Manufacturers Establishment Date
- 3.8 Market Competitive Analysis
- 3.8.1 Global Radiopharmaceuticals in Nuclear Medicine Market CR5 and HHI
- 3.8.2 Global Top 5 and 10 Radiopharmaceuticals in Nuclear Medicine Players Market Share by Revenue in 2024
- 3.8.3 2024 Radiopharmaceuticals in Nuclear Medicine Tier 1, Tier 2, and Tier 3
- 4 Radiopharmaceuticals in Nuclear Medicine Market by Type
- 4.1 Radiopharmaceuticals in Nuclear Medicine Type Introduction
- 4.1.1 Diagnostic Radiopharmaceuticals
- 4.1.2 Therapy Radiopharmaceuticals
- 4.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Type
- 4.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Type (2020-2031)
- 4.2.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Type (2020-2031)
- 4.3 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type
- 4.3.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2020 VS 2024 VS 2031)
- 4.3.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Type (2020-2031)
- 4.3.3 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Type (2020-2031)
- 5 Radiopharmaceuticals in Nuclear Medicine Market by Application
- 5.1 Radiopharmaceuticals in Nuclear Medicine Application Introduction
- 5.1.1 Oncology
- 5.1.2 Cardiology
- 5.1.3 Other
- 5.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Application
- 5.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Application (2020-2031)
- 5.2.3 Global Radiopharmaceuticals in Nuclear Medicine Sales Market Share by Application (2020-2031)
- 5.3 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application
- 5.3.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2020 VS 2024 VS 2031)
- 5.3.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Application (2020-2031)
- 5.3.3 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Application (2020-2031)
- 6 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region
- 6.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region: 2020 VS 2024 VS 2031
- 6.2 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region (2020-2031)
- 6.2.1 Global Radiopharmaceuticals in Nuclear Medicine Sales by Region (2020-2025)
- 6.2.2 Global Radiopharmaceuticals in Nuclear Medicine Sales Forecasted by Region (2025-2030)
- 6.3 North America
- 6.3.1 North America Radiopharmaceuticals in Nuclear Medicine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.3.2 North America Radiopharmaceuticals in Nuclear Medicine Sales by Country (2020-2031)
- 6.3.3 U.S.
- 6.3.4 Canada
- 6.3.5 Mexico
- 6.4 Europe
- 6.4.1 Europe Radiopharmaceuticals in Nuclear Medicine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.4.2 Europe Radiopharmaceuticals in Nuclear Medicine Sales by Country (2020-2031)
- 6.4.3 Germany
- 6.4.4 France
- 6.4.5 U.K.
- 6.4.6 Italy
- 6.4.7 Netherlands
- 6.5 Asia Pacific
- 6.5.1 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.5.2 Asia Pacific Radiopharmaceuticals in Nuclear Medicine Sales by Country (2020-2031)
- 6.5.3 China
- 6.5.4 Japan
- 6.5.5 South Korea
- 6.5.6 Southeast Asia
- 6.5.7 India
- 6.5.8 Australia
- 6.6 South America, Middle East and Africa
- 6.6.1 South America, Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales Growth Rate by Country: 2020 VS 2024 VS 2031
- 6.6.2 South America, Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Sales by Country (2020-2031)
- 6.6.3 Brazil
- 6.6.4 South Africa
- 6.6.5 Saudi Arabia
- 6.6.6 Turkey
- 6.6.6 Argentina
- 6.6.6 UAE
- 6.6.6 Egypt
- 6.6.6 Chile
- 7 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region
- 7.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region
- 7.1.1 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region: 2020 VS 2024 VS 2031
- 7.1.2 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region (2020-2025)
- 7.1.3 Global Radiopharmaceuticals in Nuclear Medicine Revenue by Region (2026-2031)
- 7.1.4 Global Radiopharmaceuticals in Nuclear Medicine Revenue Market Share by Region (2020-2031)
- 7.2 North America
- 7.2.1 North America Radiopharmaceuticals in Nuclear Medicine Revenue (2020-2031)
- 7.2.2 North America Radiopharmaceuticals in Nuclear Medicine Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.3 Europe
- 7.3.1 Europe Radiopharmaceuticals in Nuclear Medicine Revenue (2020-2031)
- 7.3.2 Europe Radiopharmaceuticals in Nuclear Medicine Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.4 Asia-Pacific
- 7.4.1 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Revenue (2020-2031)
- 7.4.2 Asia-Pacific Radiopharmaceuticals in Nuclear Medicine Revenue Share by Country: 2020 VS 2024 VS 2031
- 7.5 South America, Middle East and Africa
- 7.5.1 South America, Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Revenue (2020-2031)
- 7.5.2 South America, Middle East and Africa Radiopharmaceuticals in Nuclear Medicine Revenue Share by Country: 2020 VS 2024 VS 2031
- 8 Company Profiles
- 8.1 Aurobindo Pharma
- 8.1.1 Aurobindo Pharma Comapny Information
- 8.1.2 Aurobindo Pharma Business Overview
- 8.1.3 Aurobindo Pharma Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.1.4 Aurobindo Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
- 8.1.5 Aurobindo Pharma Recent Developments
- 8.2 Bracco Imaging
- 8.2.1 Bracco Imaging Comapny Information
- 8.2.2 Bracco Imaging Business Overview
- 8.2.3 Bracco Imaging Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.2.4 Bracco Imaging Radiopharmaceuticals in Nuclear Medicine Product Portfolio
- 8.2.5 Bracco Imaging Recent Developments
- 8.3 Cardinal Health
- 8.3.1 Cardinal Health Comapny Information
- 8.3.2 Cardinal Health Business Overview
- 8.3.3 Cardinal Health Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.3.4 Cardinal Health Radiopharmaceuticals in Nuclear Medicine Product Portfolio
- 8.3.5 Cardinal Health Recent Developments
- 8.4 Curium Pharma
- 8.4.1 Curium Pharma Comapny Information
- 8.4.2 Curium Pharma Business Overview
- 8.4.3 Curium Pharma Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.4.4 Curium Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
- 8.4.5 Curium Pharma Recent Developments
- 8.5 GE Healthcare
- 8.5.1 GE Healthcare Comapny Information
- 8.5.2 GE Healthcare Business Overview
- 8.5.3 GE Healthcare Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.5.4 GE Healthcare Radiopharmaceuticals in Nuclear Medicine Product Portfolio
- 8.5.5 GE Healthcare Recent Developments
- 8.6 Jubilant Pharma
- 8.6.1 Jubilant Pharma Comapny Information
- 8.6.2 Jubilant Pharma Business Overview
- 8.6.3 Jubilant Pharma Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.6.4 Jubilant Pharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
- 8.6.5 Jubilant Pharma Recent Developments
- 8.7 Lantheus
- 8.7.1 Lantheus Comapny Information
- 8.7.2 Lantheus Business Overview
- 8.7.3 Lantheus Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.7.4 Lantheus Radiopharmaceuticals in Nuclear Medicine Product Portfolio
- 8.7.5 Lantheus Recent Developments
- 8.8 Mundipharma
- 8.8.1 Mundipharma Comapny Information
- 8.8.2 Mundipharma Business Overview
- 8.8.3 Mundipharma Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.8.4 Mundipharma Radiopharmaceuticals in Nuclear Medicine Product Portfolio
- 8.8.5 Mundipharma Recent Developments
- 8.9 Novartis
- 8.9.1 Novartis Comapny Information
- 8.9.2 Novartis Business Overview
- 8.9.3 Novartis Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.9.4 Novartis Radiopharmaceuticals in Nuclear Medicine Product Portfolio
- 8.9.5 Novartis Recent Developments
- 8.10 SIEMENS
- 8.10.1 SIEMENS Comapny Information
- 8.10.2 SIEMENS Business Overview
- 8.10.3 SIEMENS Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.10.4 SIEMENS Radiopharmaceuticals in Nuclear Medicine Product Portfolio
- 8.10.5 SIEMENS Recent Developments
- 8.11 Bayer
- 8.11.1 Bayer Comapny Information
- 8.11.2 Bayer Business Overview
- 8.11.3 Bayer Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.11.4 Bayer Radiopharmaceuticals in Nuclear Medicine Product Portfolio
- 8.11.5 Bayer Recent Developments
- 8.12 Dongcheng
- 8.12.1 Dongcheng Comapny Information
- 8.12.2 Dongcheng Business Overview
- 8.12.3 Dongcheng Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.12.4 Dongcheng Radiopharmaceuticals in Nuclear Medicine Product Portfolio
- 8.12.5 Dongcheng Recent Developments
- 8.13 Eli Lilly
- 8.13.1 Eli Lilly Comapny Information
- 8.13.2 Eli Lilly Business Overview
- 8.13.3 Eli Lilly Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.13.4 Eli Lilly Radiopharmaceuticals in Nuclear Medicine Product Portfolio
- 8.13.5 Eli Lilly Recent Developments
- 8.14 China Isotope & Radiation
- 8.14.1 China Isotope & Radiation Comapny Information
- 8.14.2 China Isotope & Radiation Business Overview
- 8.14.3 China Isotope & Radiation Radiopharmaceuticals in Nuclear Medicine Sales, Price, Revenue and Gross Margin (2020-2025)
- 8.14.4 China Isotope & Radiation Radiopharmaceuticals in Nuclear Medicine Product Portfolio
- 8.14.5 China Isotope & Radiation Recent Developments
- 9 Value Chain and Sales Channels Analysis
- 9.1 Radiopharmaceuticals in Nuclear Medicine Value Chain Analysis
- 9.1.1 Radiopharmaceuticals in Nuclear Medicine Key Raw Materials
- 9.1.2 Raw Materials Key Suppliers
- 9.1.3 Manufacturing Cost Structure
- 9.1.4 Radiopharmaceuticals in Nuclear Medicine Production Mode & Process
- 9.2 Radiopharmaceuticals in Nuclear Medicine Sales Channels Analysis
- 9.2.1 Direct Comparison with Distribution Share
- 9.2.2 Radiopharmaceuticals in Nuclear Medicine Distributors
- 9.2.3 Radiopharmaceuticals in Nuclear Medicine Customers
- 10 Concluding Insights
- 11 Appendix
- 11.1 Reasons for Doing This Study
- 11.2 Research Methodology
- 11.3 Research Process
- 11.4 Authors List of This Report
- 11.5 Data Source
- 11.5.1 Secondary Sources
- 11.5.2 Primary Sources
- 11.6 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.